General Updates | The growing role of combination approaches in MF & agents being explored
Jean-Jacques Kiladjian
• 9 Oct 2023
In this video, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses unmet needs in patients with myelofibrosis (MF) treated with JAK inhibitors, highlighting that many patients may lose response to these agents. Prof. Kiladjian explains that combination approaches may be of benefit, and further discusses agents being explored in combination with ruxolitinib, including navitoclax, pelabresib, and navtemadlin. This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
